A meta-analysis of 13 studies with a total of 2974 patients with cancer showed that the prothrombin G20210A mutation was associated with a twofold increased risk of VTE (OR 2.14, 95% CI: 1.14–4.03) (Table 1) [17▪], similar to factor V Leiden. The gene discussed is F2; the disease is cancer.